HK1204577A1 - 生物標誌及使用溶瘤病毒和免疫調節的聯合療法 - Google Patents

生物標誌及使用溶瘤病毒和免疫調節的聯合療法

Info

Publication number
HK1204577A1
HK1204577A1 HK15105220.4A HK15105220A HK1204577A1 HK 1204577 A1 HK1204577 A1 HK 1204577A1 HK 15105220 A HK15105220 A HK 15105220A HK 1204577 A1 HK1204577 A1 HK 1204577A1
Authority
HK
Hong Kong
Prior art keywords
immunomodulation
biomarkers
combination therapies
oncolytic virus
oncolytic
Prior art date
Application number
HK15105220.4A
Other languages
English (en)
Inventor
Frank Tufaro
Charles Conrad
Juan Fueyo-Margareto
Frederick Lang
Candelaria Gomez-Manzano
W K Alfred Yung
Amy Heimberger
Original Assignee
Dnatrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnatrix Inc filed Critical Dnatrix Inc
Publication of HK1204577A1 publication Critical patent/HK1204577A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
HK15105220.4A 2012-01-25 2015-06-01 生物標誌及使用溶瘤病毒和免疫調節的聯合療法 HK1204577A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261590441P 2012-01-25 2012-01-25
US201261637191P 2012-04-23 2012-04-23
PCT/US2013/023304 WO2013112942A1 (en) 2012-01-25 2013-01-25 Biomarkers and combination therapies using oncolytic virus and immunomodulation

Publications (1)

Publication Number Publication Date
HK1204577A1 true HK1204577A1 (zh) 2015-11-27

Family

ID=47754947

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15105220.4A HK1204577A1 (zh) 2012-01-25 2015-06-01 生物標誌及使用溶瘤病毒和免疫調節的聯合療法
HK15108961.1A HK1208349A1 (zh) 2012-01-25 2015-09-14 生物標誌物及使用溶瘤病毒和免疫調節劑的組合療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15108961.1A HK1208349A1 (zh) 2012-01-25 2015-09-14 生物標誌物及使用溶瘤病毒和免疫調節劑的組合療法

Country Status (12)

Country Link
US (3) US10238698B2 (zh)
EP (2) EP2806883B1 (zh)
JP (3) JP2015508156A (zh)
KR (1) KR102081567B1 (zh)
CN (1) CN104427992B (zh)
AU (2) AU2013211871B2 (zh)
BR (1) BR112014018331A8 (zh)
CA (1) CA2862390A1 (zh)
DK (1) DK2806883T3 (zh)
HK (2) HK1204577A1 (zh)
SG (3) SG10201913784YA (zh)
WO (1) WO2013112942A1 (zh)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595736A (en) 2005-12-02 2013-05-31 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
AU2013214776B2 (en) 2012-02-02 2017-11-09 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens
US20150044224A1 (en) * 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
WO2013169971A1 (en) * 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
EP2890714A2 (en) * 2012-08-30 2015-07-08 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
CN111218429A (zh) 2013-03-14 2020-06-02 西奈山伊坎医学院 新城疫病毒及其用途
WO2014186761A2 (en) * 2013-05-17 2014-11-20 The Board Of Trustes Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-cd47 agent
CN104415335A (zh) * 2013-09-02 2015-03-18 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
DK3071697T3 (da) * 2013-11-22 2020-01-27 Dnatrix Inc Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er)
EP3110443A4 (en) * 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
US20170115291A1 (en) * 2014-05-28 2017-04-27 Dana-Farber Cancer Institute, Inc. Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
US11285194B2 (en) * 2014-10-24 2022-03-29 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
EP3271483B1 (en) 2015-03-17 2021-07-21 Mayo Foundation for Medical Education and Research Methods and materials for assessing and treating cancer
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
EP3303636B1 (en) * 2015-06-03 2021-11-10 Aelan Cell Technologies, Inc. Companion methods for il-2-based therapies and mesenchymal stem cell-based therapies
ES2861450T3 (es) 2015-07-20 2021-10-06 Virttu Biologics Ltd Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer
WO2017014296A1 (ja) * 2015-07-22 2017-01-26 国立大学法人鳥取大学 ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
KR20180048804A (ko) 2015-09-04 2018-05-10 아슬란 파마슈티컬스 피티이 엘티디 바리티닙 및 항암제를 포함하는 병용 요법
WO2017062615A2 (en) * 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
CN108697788A (zh) * 2015-10-15 2018-10-23 杜克大学 组合治疗
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
JP7089470B2 (ja) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド 抗体およびその使用方法
CA3010987A1 (en) * 2016-01-08 2017-07-13 Replimune Limited Oncolytic herpes simplex virus type 1 strain
EP3193173A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Serological autoantibodies as biomarker for colorectal cancer
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy COMBINATION OF ADENOVIRUS AND CHEMOTHERAPY AGENTS FOR CANCER CARE
KR20180102628A (ko) * 2016-01-21 2018-09-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 면역조절제의 조합물에 의한 암의 치료
CN105603085B (zh) * 2016-01-29 2019-01-29 北京泱深生物信息技术有限公司 椎间盘退行性病变的诊治靶标
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CN114028549A (zh) * 2016-02-19 2022-02-11 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
US11497781B2 (en) * 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
WO2017176289A1 (en) * 2016-04-08 2017-10-12 Celgene Corporation Uses of lenalidomide and car t-cells
GB201608918D0 (en) * 2016-05-20 2016-07-06 Aslan Pharmaceuticals Pte Ltd Method
WO2017205875A1 (en) * 2016-05-27 2017-11-30 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
US11865149B2 (en) 2016-06-17 2024-01-09 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
US20190185571A1 (en) * 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
US20190300967A1 (en) * 2016-10-13 2019-10-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
US20190275092A1 (en) 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF
EP3551226A1 (en) * 2016-12-12 2019-10-16 MultiVir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
EP3565578A1 (en) 2016-12-21 2019-11-13 Memgen LLC Armed replication-competent oncolytic adenoviruses
US11865150B2 (en) 2017-01-13 2024-01-09 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
CN108341818A (zh) * 2017-01-21 2018-07-31 南京华威医药科技开发有限公司 巴瑞克替尼及其磷酸盐的新晶型及其制备方法
CN108338994A (zh) * 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
EP3580347A4 (en) * 2017-02-08 2020-12-02 Mitra RxDx, Inc. METHOD OF PREDICTING CLINICAL OUTCOME OF ANTI-CANCER PRODUCTS
US20200046696A1 (en) * 2017-02-14 2020-02-13 Celgene Corporation Treatment of cancer with smg1-inhibitors
CN110573624A (zh) 2017-04-14 2019-12-13 永恒生物科技股份有限公司 治疗膀胱癌的方法
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
WO2019143585A1 (en) * 2018-01-17 2019-07-25 Eli Lilly And Company Compounds and methods targeting interleukin-19
CN108414660B (zh) * 2018-03-08 2020-03-20 中国药科大学 一组与肺癌早期诊断相关的血浆代谢小分子标志物的应用
CN110527696A (zh) * 2018-06-13 2019-12-03 中山大学 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用
KR102091567B1 (ko) * 2018-06-15 2020-03-20 인하대학교 산학협력단 오스테오폰틴 단백질 단편을 유효성분으로 함유하는 뇌손상 예방 또는 치료용 약학 조성물
CN110755619A (zh) * 2018-07-27 2020-02-07 复旦大学 一种人疱疹病毒裂解复制激活的宿主标志物及其用途
CN108998529A (zh) * 2018-08-30 2018-12-14 上海交通大学医学院附属上海儿童医学中心 肺腺癌检测试剂盒及检测tulp2基因甲基化水平的方法
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CA3116192A1 (en) * 2018-11-06 2020-05-14 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
CN113906298A (zh) * 2019-03-27 2022-01-07 新加坡保健服务集团有限公司 对腹膜癌扩散具有治疗意义的生物标志物
EP3946421A4 (en) * 2019-03-28 2022-12-21 Mayo Foundation for Medical Education and Research IFNBETA AS A PHARMACODYNAMIC MARKER IN ONCOLYTIC THERAPY VSV-IFNBETA-NIS
KR102199141B1 (ko) * 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
JP2022543445A (ja) 2019-08-05 2022-10-12 メゾブラスト・インターナショナル・エスアーエールエル ウイルスベクターを含む細胞組成物及び処置方法
CN110687281B (zh) * 2019-08-26 2023-05-23 中国医学科学院肿瘤医院 Pd-l1自身抗体在肿瘤预后评估中的应用
EP4023235A4 (en) * 2019-08-29 2023-03-29 Bionoxx Inc. PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER WITH VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS
WO2021061775A1 (en) * 2019-09-23 2021-04-01 Sillajen, Inc. Immune assay for monitoring response to oncolytic vaccinia virus and uses thereof
CN111337678B (zh) * 2020-02-21 2023-06-06 杭州凯保罗生物科技有限公司 与肿瘤免疫治疗效果相关的生物标志物及其应用
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
WO2021225421A1 (ko) * 2020-05-08 2021-11-11 주식회사 루닛 면역 항암제에 대한 반응을 예측하는 방법 및 시스템
JP2023525465A (ja) * 2020-05-08 2023-06-16 ルニット インコーポレイテッド 病理スライドイメージに対する免疫表現型と関連付けられた情報を提供する方法及び装置
KR102628046B1 (ko) * 2020-05-08 2024-01-23 주식회사 루닛 면역 항암제에 대한 반응을 예측하는 방법 및 시스템
CN111579788A (zh) * 2020-05-29 2020-08-25 郑州大学 一种高灵敏肿瘤标志物EPHA2的Simoa试剂盒及其应用
JP2023537103A (ja) 2020-08-10 2023-08-30 メゾブラスト・インターナショナル・エスアーエールエル 細胞組成物及び治療方法
CN112345755B (zh) * 2020-09-23 2023-06-16 杭州凯保罗生物科技有限公司 乳腺癌的生物标志物及其应用
WO2022140576A1 (en) * 2020-12-22 2022-06-30 The Brigham And Women's Hospital, Inc. Blood-based protein biomarker panel for early and accurate detection of cancer
WO2023107878A1 (en) * 2021-12-06 2023-06-15 Oncorus, Inc. Compositions and methods of seneca valley virus (svv) related cancer therapy
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
AU716045B2 (en) 1994-11-28 2000-02-17 Genetic Therapy, Inc. Vectors for tissue-specific replication
JPH11503910A (ja) 1995-04-17 1999-04-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム アデノウイルスヘルパーウイルスシステム
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US6080578A (en) 1996-12-31 2000-06-27 Onyx Pharmaceuticals, Inc. Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
WO1998039467A2 (en) 1997-03-03 1998-09-11 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
US6096718A (en) 1997-06-05 2000-08-01 Gene Targeting Corp. Tissue specific adenovirus vectors for breast cancer treatment
WO2000029599A1 (en) 1998-11-18 2000-05-25 Canji, Inc. Viral vectors with late transgene expression
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
WO2000067576A1 (en) 1999-05-12 2000-11-16 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
ATE371031T1 (de) 1999-06-08 2007-09-15 Uab Research Foundation Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
WO2001023004A1 (en) 1999-09-30 2001-04-05 The Trustees Of The University Of Pennsylvania Replication selective adenoviruses for use in cancer therapy
CA2386626A1 (en) 1999-10-15 2001-04-26 Richard Murphy Targeted vectors
WO2001058940A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
US20030211477A1 (en) 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
CN104059147A (zh) 2003-06-27 2014-09-24 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
US20070134202A1 (en) 2003-10-15 2007-06-14 The New Industry Reserch Organization Cancer gene therapeutic drug
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US7655459B2 (en) 2004-03-31 2010-02-02 Tomoki Todo Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer
CA2581674A1 (en) 2004-07-13 2006-01-19 The University Of British Columbia Indoleamine 2,3-dioxygenase (ido) inhibitors
LT2650020T (lt) 2005-05-06 2016-12-12 Providence Health & Services - Oregon Trimerinio ox40-immunoglobulino sulietas baltymas ir naudojimo būdai
MX2007015942A (es) * 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
CA2621127C (en) 2005-08-31 2014-02-25 Oncolytics Biotech Inc. Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
WO2007103825A2 (en) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Combination therapy with oncolytic adenovirus
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
CA2734908A1 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
AU2009332883B2 (en) * 2008-12-22 2015-05-21 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
CN101607985B (zh) 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
WO2010130053A1 (en) 2009-05-15 2010-11-18 University Health Network COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGIC CANCERS TARGETING THE SIRPα - CD47 INTERACTION
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
WO2011041613A2 (en) * 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
EP2504028A4 (en) * 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
EP2407177A1 (en) 2010-07-13 2012-01-18 Institut Gustave Roussy Adenovirus vaccine vectors
EP2383577A1 (en) 2010-04-30 2011-11-02 Deutsches Krebsforschungszentrum Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
KR102049817B1 (ko) 2011-08-01 2019-12-02 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
AU2013201121A1 (en) * 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
AU2013214776B2 (en) 2012-02-02 2017-11-09 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens
US20160143967A1 (en) 2013-06-18 2016-05-26 Dnatrix, Inc. Treatment of brain cancer with oncolytic adenovirus

Also Published As

Publication number Publication date
CN104427992B (zh) 2017-12-19
WO2013112942A1 (en) 2013-08-01
US11065285B2 (en) 2021-07-20
CA2862390A1 (en) 2013-08-01
SG11201404313YA (en) 2014-10-30
JP2015508156A (ja) 2015-03-16
AU2013211871B2 (en) 2017-12-14
AU2018201776A1 (en) 2018-04-05
EP3578198A1 (en) 2019-12-11
US10238698B2 (en) 2019-03-26
US20200330533A1 (en) 2020-10-22
AU2013211871A1 (en) 2014-08-14
EP2806883A1 (en) 2014-12-03
CN104427992A (zh) 2015-03-18
US20140377221A1 (en) 2014-12-25
US20190269744A1 (en) 2019-09-05
JP2019066482A (ja) 2019-04-25
BR112014018331A2 (zh) 2017-06-20
SG10201604654RA (en) 2016-07-28
SG10201913784YA (en) 2020-03-30
EP2806883B1 (en) 2019-04-24
JP2021103174A (ja) 2021-07-15
DK2806883T3 (da) 2019-07-22
HK1208349A1 (zh) 2016-03-04
BR112014018331A8 (pt) 2017-07-11
KR20150008846A (ko) 2015-01-23
KR102081567B1 (ko) 2020-02-26

Similar Documents

Publication Publication Date Title
HK1208349A1 (zh) 生物標誌物及使用溶瘤病毒和免疫調節劑的組合療法
HK1211851A1 (zh) 抗登革病毒抗體和其用途
HK1204809A1 (zh) 自動駕駛儀及其方法
HK1202545A1 (zh) 新型二氮雜螺環烷烴和氮雜螺環烷烴
HK1207092A1 (zh) 抗- 抗體及其用途
PL2855662T3 (pl) Rekombinowane mikroorganizmy i ich zastosowania
EP2859089A4 (en) RECOMBINANT MICROORGANISMS AND USES THEREOF
EP2855690A4 (en) RECOMBINANT MICROORGANISMS AND USES THEREOF
SG11201501254RA (en) Recombinant microorganisms and uses therefor
GB201201100D0 (en) Polypeptides and methods
HK1210949A1 (zh) 組合及其用途
HK1205523A1 (zh) 抗-大-內皮素- 抗體及其用途
HK1199269A1 (zh) 抗- 的抗體及其用途
GB201321144D0 (en) Improved oncolytic viruses
GB201202016D0 (en) Noise and projection fairing
EP2938415A4 (en) MATERIALS AND METHOD
ZA201501658B (en) Ventilator and blade therefor
EP2920312A4 (en) ONCOLYTIC HSV1 VECTORS AND METHODS OF USING SAME
GB201214769D0 (en) Methodsa and peptides
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201210303D0 (en) Polypeptides and methods
GB201202945D0 (en) Novel cancer therapies and methods